Chugai Pharmaceutical Co., Ltd. (4519.T)

5,783.00 -16.00 (-0.28%) 市場開市。 截至 09:44AM JST。

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 7,604

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Osamu Okuda	President, CEO & Representative Director	218M	無	1963
Mr. Iwaaki Taniguchi	Executive VP, Head of Finance Supervisory Division, CFO & Director	無	無	1967
Toshiya Sasai	Executive of Investor Relations Group & Corporate Communications Department	無	無	無
Mr. Masayoshi Higuchi	VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.	無	無	無
Junichi Takano	Head of Marketing & Sales Division	無	無	無
Mr. Shinji Hidaka	Executive Vice President	無	無	無
Mr. Junichi Ebihara	Executive Vice President	無	無	無
Dr. Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	無	無	1960
Mr. Tetsuya Yamaguchi	Executive VP & Head of PHC Solution Unit	無	無	無
Mr. Yoshiyuki Yano	Executive Vice President	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 JPY。

描述

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

公司管治

截至 2024年6月1日 止，Chugai Pharmaceutical Co., Ltd. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：1；董事會：7；股東權利：2；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。